株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

MGB Biopharma Limited:製品パイプライン分析

MGB Biopharma Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 319985
出版日 ページ情報 英文 25 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
MGB Biopharma Limited:製品パイプライン分析 MGB Biopharma Limited - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 25 Pages
概要

MGB Biopharma Limited は、感受性および耐性菌に対して特殊な抗菌作用を持った小分子の開発に力を注いているバイオ製薬会社です。同社の 製品は、防かび、抗ウィルス、駆虫性の特性を持っており、グラム陽性菌に対して使われます。また、大学と連携して感染症の治療薬の開発にも取り組んでいます。

当レポートでは、MGB Biopharma Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

MGB Biopharma Limitedの基本情報

  • MGB Biopharma Limitedの概要
  • 主要情報
  • 企業情報

MGB Biopharma Limited:R&Dの概要

  • 主な治療範囲

MGB Biopharma Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

MGB Biopharma Limited:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

MGB Biopharma Limited:薬剤プロファイル

  • MGBBP-3
  • AbMGB
  • AfMGB
  • ApMGB
  • Small Molecule for Viral Infection

MGB Biopharma Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

MGB Biopharma Limited:最近のパイプライン動向

MGB Biopharma Limited:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07908CDB

Summary

Global Markets Direct's, 'MGB Biopharma Limited - Product Pipeline Review - 2015', provides an overview of the MGB Biopharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MGB Biopharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of MGB Biopharma Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MGB Biopharma Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MGB Biopharma Limited's pipeline products

Reasons to buy

  • Evaluate MGB Biopharma Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MGB Biopharma Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MGB Biopharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MGB Biopharma Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MGB Biopharma Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MGB Biopharma Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MGB Biopharma Limited Snapshot
    • MGB Biopharma Limited Overview
    • Key Information
    • Key Facts
  • MGB Biopharma Limited - Research and Development Overview
    • Key Therapeutic Areas
  • MGB Biopharma Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • MGB Biopharma Limited - Pipeline Products Glance
    • MGB Biopharma Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • MGB Biopharma Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • MGB Biopharma Limited - Drug Profiles
    • MGBBP-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Synthesis for Fungal Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Synthesis for Gram-Negative Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Synthesis for Parasitic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Synthesis for Viral Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • MGB Biopharma Limited - Pipeline Analysis
    • MGB Biopharma Limited - Pipeline Products by Target
    • MGB Biopharma Limited - Pipeline Products by Route of Administration
    • MGB Biopharma Limited - Pipeline Products by Molecule Type
    • MGB Biopharma Limited - Pipeline Products by Mechanism of Action
  • MGB Biopharma Limited - Recent Pipeline Updates
  • MGB Biopharma Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MGB Biopharma Limited, Key Information
  • MGB Biopharma Limited, Key Facts
  • MGB Biopharma Limited - Pipeline by Indication, 2015
  • MGB Biopharma Limited - Pipeline by Stage of Development, 2015
  • MGB Biopharma Limited - Monotherapy Products in Pipeline, 2015
  • MGB Biopharma Limited - Phase I, 2015
  • MGB Biopharma Limited - Preclinical, 2015
  • MGB Biopharma Limited - Discovery, 2015
  • MGB Biopharma Limited - Pipeline by Target, 2015
  • MGB Biopharma Limited - Pipeline by Route of Administration, 2015
  • MGB Biopharma Limited - Pipeline by Molecule Type, 2015
  • MGB Biopharma Limited - Pipeline Products by Mechanism of Action, 2015
  • MGB Biopharma Limited - Recent Pipeline Updates, 2015

List of Figures

  • MGB Biopharma Limited - Pipeline by Top 10 Indication, 2015
  • MGB Biopharma Limited - Pipeline by Stage of Development, 2015
  • MGB Biopharma Limited - Monotherapy Products in Pipeline, 2015
  • MGB Biopharma Limited - Pipeline by Top 10 Target, 2015
  • MGB Biopharma Limited - Pipeline by Top 10 Route of Administration, 2015
  • MGB Biopharma Limited - Pipeline by Top 10 Molecule Type, 2015
  • MGB Biopharma Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top